Physician profile
Adam A Debusk
NPI 1821359415
$22,576.46
in general payments reported to CMS, 2019-2025
17 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $223 · 2021: $62.96 · 2022: $369 · 2023: $12K · 2024: $8,349 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,650 · Food and Beverage: $2,141 · Travel and Lodging: $927 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,650.00 |
| Food and Beverage | $2,140.95 |
| Travel and Lodging | $926.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,057.66 | 2020-2023 | Uplizna, Tepezza |
| Amgen INC. | $8,457.54 | 2024-2025 | Uplizna, Tepezza |
| Mallinckrodt Hospital Products INC. | $435.51 | 2022-2025 | Acthar |
| Genentech USA, INC. | $379.09 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $319.59 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $260.09 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $232.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $132.18 | 2023-2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $82.95 | 2022 | |
| Biogen, INC. | $65.33 | 2019 | |
| Ucb, INC. | $55.51 | 2023 | |
| Genzyme Corporation | $33.47 | 2019-2020 | |
| Abbvie INC. | $24.18 | 2025 | |
| Merz North America, INC. | $23.06 | 2020 | |
| Allergan, INC. | $17.70 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$36,940,762.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Debusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.